Goodsurance

Drug prices & Part D

KFF: The Part D Subsidy Program Being Dropped Cost 9.8 Billion Dollars and Held Premiums Down for 24.9 Million Enrollees

A KFF analysis published after CMS's July 28 announcement tallies what the two-year Part D stabilization demonstration achieved, and describes the shrinking standalone drug plan market those enrollees will now navigate without that buffer.

By the Goodsurance editorial teamJuly 29, 2026

When CMS announced on July 28, 2026 that it was ending the Part D Premium Stabilization Demonstration after 2026, it cited plan sponsors' growing familiarity with the redesigned benefit as justification. A KFF Quick Takes analysis published in response puts concrete numbers on what the program achieved, and on the market the 24.9 million people enrolled in standalone prescription drug plans (PDPs) will now face.

The demonstration, which ran in plan years 2025 and 2026, cost a total of 9.8 billion dollars in federal outlay across both years. According to Medicare Payment Advisory Commission (MedPAC) data cited by KFF, the subsidy reduced the average standalone PDP premium by 26 dollars per month in 2025 and 16 dollars per month in 2026. PDP enrollment rose from 22.8 million at the start of 2024 to 24.9 million in 2026, a growth KFF attributes partly to the subsidy keeping standalone plan premiums more competitive with Medicare Advantage drug coverage.

For 2027, one statutory protection remains: the Inflation Reduction Act's premium stabilization provision caps the annual increase in the base beneficiary premium at 6 percent per year through 2029. The 2027 base beneficiary premium is set at 41.33 dollars, exactly 6 percent above the 2026 level of 38.99 dollars. Plan-specific premiums for standalone PDPs are built on top of that base figure and can run substantially higher. Without the demonstration's additional buffer, plan-level premiums could rise more sharply when 2027 plans are announced this fall.

The backdrop for this shift is a standalone PDP market that has already contracted considerably. In 2026, only 360 PDPs were offered nationwide, down 22 percent from 464 in 2025 and a sharp decline from roughly 30 plan options per average beneficiary in 2021 to just 11 today. KFF notes that the demonstration's removal coincides with both reduced plan availability and pricing pressure in the standalone drug plan segment.

Enrollees in standalone PDPs who want to compare 2027 options can do so beginning October 15, when the annual enrollment period opens.

In plain words

For two years, the government ran a program to keep Medicare drug plan premiums lower. It cost 9.8 billion dollars total and saved the average enrollee about 26 dollars a month in 2025 and 16 dollars a month in 2026. About 25 million people were in these standalone drug plans. That program is now ending. There is still a law that limits how much the base premium can go up each year, but individual plan premiums can still rise above that floor. There are also fewer drug plans to choose from than before. During the fall enrollment period starting October 15, enrollees should compare their options carefully.

Understand the basics first

Source: KFF
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

August 4, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026